<DOC>
	<DOCNO>NCT02465203</DOCNO>
	<brief_summary>Follow-up viral activity , change liver function safety patient SVR24 feeder study</brief_summary>
	<brief_title>3-year Follow-up Study Assess Viral Activity Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study</brief_title>
	<detailed_description>The purpose study follow patient feeder study achieve SVR24 assess viral activity , ass change liver function disease , post-treatment safety time .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>1 . Males female age â‰¥18 2 . Have previously complete Novartissponsored hepatitis C study receive alisporivir direct antiviral agent ( DAA ) 3 . Have achieve SVR24 1 . Use investigational drug within 5 halflives enrollment , within 30 day medication , whichever longer . 2 . Previous use course hepatitis C therapy since end Novartissponsored hepatitis C study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Hepatitis C , chronic</keyword>
</DOC>